Humacyte Inc. (HUMA) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 1.41 High: 1.47

52 Week Range

Low: 1.15 High: 9.97

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $226 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    30.28

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    -0.31

  • ROEROE information

    -8.51 %

  • ROCEROCE information

    -851.67 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    --

  • EPSEPS information

    -1.26

5 Years Aggregate

CFO

$-352.98 Mln

EBITDA

$-524.57 Mln

Net Profit

$-163.17 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Humacyte (HUMA)
-71.68 -27.04 -69.05 -64.16 -42.24 -- --
BSE Sensex
2.61 3.71 5.78 8.89 11.76 20.11 11.35
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 29-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
Humacyte (HUMA)
76.98 34.60 -70.90
S&P Small-Cap 600
7.01 13.89 -17.42
BSE Sensex
8.10 18.74 4.44

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
38.55 10,593.45 21.84 23.13
306.35 8,570.17 22.78 66.44
27.82 10,589.59 -- -28.77
107.24 10,559.67 32.44 14.16

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple...  therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Address: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713  Read more

  • Founder, President, CEO & Director

    Dr. Laura E. Niklason M.D., Ph.D.

  • Founder, President, CEO & Director

    Dr. Laura E. Niklason M.D., Ph.D.

  • Headquarters

    Durham, NC

  • Website

    https://humacyte.com

Edit peer-selector-edit
loading...
loading...

FAQs for Humacyte Inc. (HUMA)

The total asset value of Humacyte Inc (HUMA) stood at $ 138 Mln as on 31-Dec-24

The share price of Humacyte Inc (HUMA) is $1.43 (NASDAQ) as of 29-Apr-2025 16:13 EDT. Humacyte Inc (HUMA) has given a return of -42.24% in the last 3 years.

Humacyte Inc (HUMA) has a market capitalisation of $ 226 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Humacyte Inc (HUMA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Humacyte Inc (HUMA) and enter the required number of quantities and click on buy to purchase the shares of Humacyte Inc (HUMA).

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Address: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713

The CEO & director of Dr. Laura E. Niklason M.D., Ph.D.. is Humacyte Inc (HUMA), and CFO & Sr. VP is Dr. Laura E. Niklason M.D., Ph.D..

There is no promoter pledging in Humacyte Inc (HUMA).

Humacyte Inc. (HUMA) Ratios
Return on equity(%)
760.17
Operating margin(%)
--
Net Margin(%)
--
Dividend yield(%)
--

No, TTM profit after tax of Humacyte Inc (HUMA) was $0 Mln.